Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

408
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
408
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

611
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
611
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

577
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
577
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.4K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.4K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Scandinavian journal of rheumatology·2017
Same author

Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients.

Clinical and experimental rheumatology·2014
Same author

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.

Annals of the rheumatic diseases·2006
Same author

The Lupus Foundation as an additional source for case ascertainment: developing a community-based lupus registry.

Arthritis care and research : the official journal of the Arthritis Health Professions Association·2003
Same author

The assessment of the patient with systemic sclerosis. Introduction.

Clinical and experimental rheumatology·2003
Same author

Assessment of disease severity and prognosis.

Clinical and experimental rheumatology·2003
Same journal

Metabolic and endocrine aspects of rheumatic disease.

Clinics in rheumatic diseases·1986
Same journal

Muscle 'contractures' and the 'stiff-man' syndrome.

Clinics in rheumatic diseases·1986
Same journal

Hypophosphatasia.

Clinics in rheumatic diseases·1986
Same journal

Alkaptonuria.

Clinics in rheumatic diseases·1986
Same journal

Diabetes mellitus and rheumatic disease.

Clinics in rheumatic diseases·1986
Same journal

Musculoskeletal manifestations of primary hyperparathyroidism.

Clinics in rheumatic diseases·1986
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

913

Progressive systemic sclerosis.

T A Medsger

    Clinics in Rheumatic Diseases
    |December 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Future therapeutic trials for progressive systemic sclerosis (PSS) require robust, prospective, multicenter studies. Enhanced patient classification, validated assessment tools, and longer study durations are crucial for reliable results.

    More Related Videos

    Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
    04:44

    Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

    Published on: June 16, 2020

    20.9K
    A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
    06:49

    A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

    Published on: October 6, 2015

    21.0K

    Related Experiment Videos

    Last Updated: Feb 17, 2026

    Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
    10:21

    Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

    Published on: September 20, 2024

    913
    Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
    04:44

    Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

    Published on: June 16, 2020

    20.9K
    A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
    06:49

    A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

    Published on: October 6, 2015

    21.0K

    Area of Science:

    • Rheumatology and Immunology
    • Clinical Trial Design and Methodology

    Background:

    • Current therapeutic trials for progressive systemic sclerosis (PSS) are limited by convenience, often being short-term, retrospective, and single-institution studies.
    • This limits the ability to draw definitive conclusions regarding treatment efficacy.

    Purpose of the Study:

    • To outline critical improvements needed for future therapeutic trials in progressive systemic sclerosis.
    • To emphasize the necessity for more rigorous study designs to advance treatment understanding.

    Main Methods:

    • Proposes the expansion of efforts to include controlled, prospective, multicenter studies with adequate patient numbers.
    • Highlights the need for careful patient classification into meaningful disease subsets.
    • Advocates for the development and validation of objective criteria for disease staging, severity, and change assessment, including skin and internal organ involvement.

    Main Results:

    • Current trial limitations necessitate a shift towards more comprehensive and methodologically sound research.
    • The abstract identifies key areas for improvement in trial design and patient assessment.

    Conclusions:

    • Future progress in PSS treatment hinges on implementing rigorous clinical epidemiological research.
    • Careful planning, biostatistical expertise, and attention to disease duration are essential for successful therapeutic trials.
    • Focusing on early-stage disease and validated outcome measures will yield more reliable data.